# Flumatinib

Source: https://onco.cc/drugs/flumatinib/  
OnCo record `flumatinib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Flumatinib is Hansoh Pharma's second-generation BCR-ABL inhibitor, approved in China in 2019 for newly diagnosed chronic-phase chronic myeloid leukaemia.

## Summary

Flumatinib is an imatinib derivative developed by Hansoh Pharma. The NMPA approved it in November 2019 for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase, after the FESTnd phase 3 trial reported deeper and faster molecular responses than imatinib. It is the first BCR-ABL inhibitor discovered and developed in China.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-16
- Also known as: Xinfu
- Tags: china; nmpa-approved
- Code: HH-GV-678
- Modality: Oral second-generation BCR-ABL tyrosine kinase inhibitor
- Mechanism: Blocks the BCR-ABL fusion kinase that drives chronic myeloid leukaemia, with higher potency than imatinib.
- Approvals: CN 2019: Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia, chronic phase

## Sources

- ClinicalTrials.gov: trials of flumatinib: https://clinicaltrials.gov/search?intr=flumatinib

## Connected records

- cancers: [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [BCR::ABL1 (Philadelphia chromosome)](https://onco.cc/targets/bcr-abl/)
- companies: [Hansoh Pharmaceutical](https://onco.cc/companies/hansoh-pharma/)

---
JSON: https://onco.cc/api/v1/entities/flumatinib.json